Mirum 與 Kodiak Sciences 分享研究結果
Mirum and Kodiak Sciences share study results
Updated at: September 28, 2026 at 01:45 AM
2026年9月28日，生物技術產業出現了來自兩家大型企業的重要更新：Mirum Pharmaceuticals與Kodiak Sciences。
On September 28, 2026, the biotechnology sector saw significant updates from two major companies: Mirum Pharmaceuticals and Kodiak Sciences.
這些是涉及不同臨床試驗與治療重點的完全獨立企業更新。
These are entirely separate corporate updates involving distinct clinical trials and therapeutic focuses.
Mirum Pharmaceuticals舉辦了一場投資人電話會議，分享其針對慢性丁型肝炎病毒（HDV）的brelovitug藥物在第三期AZURE-1研究中的正面初步結果。
Mirum Pharmaceuticals hosted an investor call to share positive topline results from their Phase 3 AZURE-1 study of brelovitug, which targets chronic hepatitis delta virus (HDV).
此前，該公司剛成功獲得FDA批准其用於治療進行性骨化性纖維發育不良（FOP）的藥物Atebrioz。
This follows the company's recent success in receiving FDA approval for their FOP treatment, Atebrioz.
與此同時，Kodiak Sciences舉辦了一場網路廣播，報告其DAYBREAK樞紐性第三期研究的發現。
Meanwhile, Kodiak Sciences held a webcast to report findings from their DAYBREAK pivotal Phase 3 study.
該試驗評估了其針對濕性老年性黃斑部病變（wet AMD）患者的候選藥物Zenkuda與KSI-501。
This trial evaluated their candidates, Zenkuda and KSI-501, for patients suffering from wet age-related macular degeneration (wet AMD).
透過觀察這兩家公司，我們可以發現明確的區別：Mirum持續專注於罕見疾病，而Kodiak Sciences則聚焦於視網膜健康。
By looking at these companies, we see a clear divide: Mirum remains focused on rare diseases, while Kodiak Sciences concentrates on retinal health.
了解這些是獨立的里程碑，有助於投資人與研究人員避免混淆不同的藥物、研究目標與市場策略。
Understanding that these are independent milestones helps investors and researchers avoid confusion between different drugs, study goals, and market strategies.
